Jacobs Levy Equity Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Jacobs Levy Equity Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-9,348	Closed	-$85K	–	1086
2016 Q2	$85K	Sell	9,348 -30,604	-77%	-$367K	﹤0.01%	1104
2016 Q1	$336K	Buy	39,952 +39,526	+9,278%	+$330K	0.01%	835
2015 Q4	$5K	Sell	426 -12,156	-97%	-$334K	﹤0.01%	788
2015 Q3	$766K	Buy	12,582 +6,197	+97%	+$447K	0.02%	522
2015 Q2	$498K	Buy	6,385 +3,914	+158%	+$328K	0.01%	570
2015 Q1	$168K	Sell	2,471 -12,417	-83%	-$1.06M	﹤0.01%	720
2014 Q4	$1.38M	Buy	14,888 +11,825	+386%	+$1.22M	0.02%	444
2014 Q3	$323K	Buy	3,063 +26	+0.9%	+$3.62K	0.01%	666
2014 Q2	$435K	Buy	+3,037	New	+$444K	0.01%	662

Other funds holding MDGL

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jacobs Levy Equity Management's MDGL Position: Q3 2016 in Review

Jacobs Levy Equity Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2016, closing a stake of 9,348 shares — an estimated $85K sold.

Jacobs Levy Equity Management first reported a position in MDGL in Q2 2014 and held it in 9 quarters. The position peaked at $1.38M in Q4 2014. 31 funds tracked by Wall St. Rank hold MDGL as of Q3 2016.

Jacobs Levy Equity Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Jacobs Levy Equity Management sold 9,348 Madrigal Pharmaceuticals shares in Q3 2016, an estimated $85K.
Jacobs Levy Equity Management first reported a position in Madrigal Pharmaceuticals in Q2 2014 and held it in 9 quarters.
Jacobs Levy Equity Management's Madrigal Pharmaceuticals position peaked at $1.38M in Q4 2014.
31 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2016, filed 14 Nov 2016.